• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在群体药代动力学研究中存在人为异常值时的贝叶斯分层非线性混合模型。

A Bayesian hierarchical nonlinear mixture model in the presence of artifactual outliers in a population pharmacokinetic study.

机构信息

Department of Biostatistics, School of Medicine, Vanderbilt University, Nashville, TN, USA.

出版信息

J Pharmacokinet Pharmacodyn. 2011 Oct;38(5):613-36. doi: 10.1007/s10928-011-9211-7. Epub 2011 Aug 17.

DOI:10.1007/s10928-011-9211-7
PMID:21847635
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3182101/
Abstract

The purpose of this study is to develop a statistical methodology to handle a large proportion of artifactual outliers in a population pharmacokinetic (PK) modeling. The motivating PK data were obtained from a population PK study to examine associations between PK parameters such as clearance of dexmedetomidine (DEX) and cytochrome P450 2A6 phenotypes. The blood samples were sparsely sampled from patients in intensive care units (ICUs) while different doses of DEX were continuously infused. Conventional population PK analysis of these data revealed several challenges and intricacies. Especially, there was strong evidence that some plasma drug concentrations were artifactually high and likely contaminated with the infused drug due to blood sampling processes that are sometimes unavoidable in an ICU setting. If not addressed, or if arbitrarily excluded, these outlying values could lead to biased estimates of PK parameters and miss important relationships between PK parameters and covariates due to increased variability. We propose a novel population PK model, a Bayesian hierarchical nonlinear mixture model, to accommodate the artifactual outliers using a finite mixture as the residual error model. Our results showed that the proposed model handles the outliers well. We also conducted simulation studies with a varying proportion of the outliers. These simulation results showed that the proposed model can accommodate the outliers well so that the estimated PK parameters are less biased.

摘要

本研究旨在开发一种统计方法,以处理群体药代动力学(PK)建模中大量人为异常值。本研究的 PK 数据来源于一项 PK 研究,旨在探讨去甲肾上腺素(DEX)清除率等 PK 参数与细胞色素 P450 2A6 表型之间的关系。这些血液样本是从重症监护病房(ICU)的患者中稀疏采集的,同时持续输注不同剂量的 DEX。对这些数据进行常规的群体 PK 分析揭示了一些挑战和复杂性。特别是,有强烈的证据表明,由于 ICU 环境中有时不可避免的采血过程,一些血浆药物浓度人为地过高,并且可能受到输注药物的污染。如果不加以处理,或者任意排除这些异常值,这些异常值可能会导致 PK 参数的估计值出现偏差,并由于变异性增加而错过 PK 参数与协变量之间的重要关系。我们提出了一种新的群体 PK 模型,即贝叶斯层次非线性混合模型,通过使用有限混合作为残差误差模型来适应人为异常值。研究结果表明,所提出的模型能够很好地处理异常值。我们还进行了具有不同比例异常值的模拟研究。这些模拟结果表明,所提出的模型能够很好地适应异常值,从而使估计的 PK 参数的偏差更小。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4be9/3182101/044a92654b8a/nihms325570f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4be9/3182101/07844392083a/nihms325570f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4be9/3182101/deecf1fe4742/nihms325570f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4be9/3182101/a0570989f58b/nihms325570f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4be9/3182101/f609f5e8f85a/nihms325570f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4be9/3182101/832f16931dd1/nihms325570f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4be9/3182101/044a92654b8a/nihms325570f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4be9/3182101/07844392083a/nihms325570f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4be9/3182101/deecf1fe4742/nihms325570f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4be9/3182101/a0570989f58b/nihms325570f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4be9/3182101/f609f5e8f85a/nihms325570f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4be9/3182101/832f16931dd1/nihms325570f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4be9/3182101/044a92654b8a/nihms325570f6.jpg

相似文献

1
A Bayesian hierarchical nonlinear mixture model in the presence of artifactual outliers in a population pharmacokinetic study.在群体药代动力学研究中存在人为异常值时的贝叶斯分层非线性混合模型。
J Pharmacokinet Pharmacodyn. 2011 Oct;38(5):613-36. doi: 10.1007/s10928-011-9211-7. Epub 2011 Aug 17.
2
CYP2A6 genetic variation and dexmedetomidine disposition.CYP2A6 基因变异与右美托咪定处置。
Eur J Clin Pharmacol. 2012 Jun;68(6):937-42. doi: 10.1007/s00228-011-1208-z. Epub 2012 Jan 21.
3
Population Pharmacokinetic Model of Dexmedetomidine in a Heterogeneous Group of Patients.右美托咪定在异质性患者群体中的群体药代动力学模型
J Clin Pharmacol. 2020 Nov;60(11):1461-1473. doi: 10.1002/jcph.1647. Epub 2020 Jun 5.
4
Pharmacokinetics of Dexmedetomidine in Infants and Children After Orthotopic Liver Transplantation.右美托咪定在肝移植儿童中的药代动力学。
Anesth Analg. 2020 Jan;130(1):209-216. doi: 10.1213/ANE.0000000000003761.
5
Population Pharmacokinetics of Dexmedetomidine in Infants.右美托咪定在婴儿中的群体药代动力学
J Clin Pharmacol. 2017 Sep;57(9):1174-1182. doi: 10.1002/jcph.904. Epub 2017 Apr 25.
6
The pharmacokinetics of dexmedetomidine during long-term infusion in critically ill pediatric patients. A Bayesian approach with informative priors.右美托咪定在危重症儿科患者长期输注期间的药代动力学。一种采用信息先验的贝叶斯方法。
J Pharmacokinet Pharmacodyn. 2016 Jun;43(3):315-24. doi: 10.1007/s10928-016-9474-0. Epub 2016 May 24.
7
Pharmacokinetics of dexmedetomidine during analgosedation in ICU patients.ICU 患者镇静性镇痛时右美托咪定的药代动力学。
J Pharmacokinet Pharmacodyn. 2018 Apr;45(2):277-284. doi: 10.1007/s10928-017-9564-7. Epub 2017 Dec 30.
8
Dexmedetomidine Pharmacology in Neonates and Infants After Open Heart Surgery.新生儿及婴幼儿心脏直视手术后右美托咪定的药理学
Anesth Analg. 2016 May;122(5):1556-66. doi: 10.1213/ANE.0000000000000869.
9
Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine in healthy subjects.健康受试者静脉注射和鼻内给予右美托咪定的基于机制的群体药代动力学和药效学建模
Eur J Clin Pharmacol. 2015 Oct;71(10):1197-207. doi: 10.1007/s00228-015-1913-0. Epub 2015 Aug 2.
10
Population analysis to assess the influence of age and body weight on pharmacokinetics and pharmacodynamics of dexmedetomidine in New Zealand White rabbits.
Biopharm Drug Dispos. 2020 Jul;41(7):307-316. doi: 10.1002/bdd.2248. Epub 2020 Jul 23.

引用本文的文献

1
Using Real-World Data to Externally Evaluate Population Pharmacokinetic Models of Dexmedetomidine in Children and Infants.利用真实世界数据对外评估右美托咪定在儿童和婴儿中的群体药代动力学模型。
J Clin Pharmacol. 2024 Aug;64(8):963-974. doi: 10.1002/jcph.2434. Epub 2024 Mar 28.
2
Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation.群体药代动力学与基于模型的精准剂量给药用于接受造血干细胞移植患者的美法仑优化采样策略。
Clin Pharmacokinet. 2018 May;57(5):625-636. doi: 10.1007/s40262-017-0581-x.
3
The pharmacokinetics of dexmedetomidine during long-term infusion in critically ill pediatric patients. A Bayesian approach with informative priors.右美托咪定在危重症儿科患者长期输注期间的药代动力学。一种采用信息先验的贝叶斯方法。
J Pharmacokinet Pharmacodyn. 2016 Jun;43(3):315-24. doi: 10.1007/s10928-016-9474-0. Epub 2016 May 24.
4
Population Pharmacokinetics of Fentanyl in the Critically Ill.芬太尼在危重症患者中的群体药代动力学
Crit Care Med. 2016 Jan;44(1):64-72. doi: 10.1097/CCM.0000000000001347.
5
Interpatient variability in dexmedetomidine response: a survey of the literature.右美托咪定反应的患者间变异性:文献综述
ScientificWorldJournal. 2014 Jan 16;2014:805013. doi: 10.1155/2014/805013. eCollection 2014.
6
Population pharmacokinetics of dexmedetomidine in critically ill patients.危重症患者右美托咪定的群体药代动力学。
Clin Drug Investig. 2013 Aug;33(8):579-87. doi: 10.1007/s40261-013-0101-1.
7
CYP2A6 genetic variation and dexmedetomidine disposition.CYP2A6 基因变异与右美托咪定处置。
Eur J Clin Pharmacol. 2012 Jun;68(6):937-42. doi: 10.1007/s00228-011-1208-z. Epub 2012 Jan 21.

本文引用的文献

1
Effects of variation in the human alpha2A- and alpha2C-adrenoceptor genes on cognitive tasks and pain perception.人类α2A-和α2C-肾上腺素能受体基因变异对认知任务和疼痛感知的影响。
Eur J Pain. 2010 Feb;14(2):154-9. doi: 10.1016/j.ejpain.2009.04.003. Epub 2009 May 6.
2
The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion.残差误差或相关结构的错误设定对协变量纳入的I型错误率的影响。
J Pharmacokinet Pharmacodyn. 2009 Feb;36(1):81-99. doi: 10.1007/s10928-009-9112-1. Epub 2009 Feb 14.
3
Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial.右美托咪定与劳拉西泮镇静对机械通气患者急性脑功能障碍的影响:MENDS随机对照试验
JAMA. 2007 Dec 12;298(22):2644-53. doi: 10.1001/jama.298.22.2644.
4
Ethnic and genetic determinants of cardiovascular response to the selective alpha 2-adrenoceptor agonist dexmedetomidine.心血管对选择性α2-肾上腺素能受体激动剂右美托咪定反应的种族和遗传决定因素。
Hypertension. 2008 Feb;51(2):406-11. doi: 10.1161/HYPERTENSIONAHA.107.098939. Epub 2007 Dec 10.
5
A phase I, two-center study of the pharmacokinetics and pharmacodynamics of dexmedetomidine in children.右美托咪定在儿童体内的药代动力学和药效学的一项I期、双中心研究。
Anesthesiology. 2006 Dec;105(6):1098-110. doi: 10.1097/00000542-200612000-00009.
6
Bayesian analysis of population PK/PD models: general concepts and software.群体药代动力学/药效学模型的贝叶斯分析:一般概念与软件
J Pharmacokinet Pharmacodyn. 2002 Jun;29(3):271-307. doi: 10.1023/a:1020206907668.
7
Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive caret.右美托咪定输注用于需要重症监护的术后患者镇静的药代动力学
Br J Anaesth. 2002 May;88(5):669-75. doi: 10.1093/bja/88.5.669.
8
Modeling pharmacokinetic data using heavy-tailed multivariate distributions.使用重尾多元分布对药代动力学数据进行建模。
J Biopharm Stat. 2000 Aug;10(3):369-81. doi: 10.1081/BIP-100102500.
9
Generalized nonlinear models for pharmacokinetic data.药代动力学数据的广义非线性模型。
Biometrics. 2000 Mar;56(1):81-8. doi: 10.1111/j.0006-341x.2000.00081.x.
10
Influence of cardiac output on dexmedetomidine pharmacokinetics.心输出量对右美托咪定药代动力学的影响。
J Pharm Sci. 2000 Apr;89(4):519-27. doi: 10.1002/(SICI)1520-6017(200004)89:4<519::AID-JPS9>3.0.CO;2-U.